We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine

The global breast cancer burden

    John R Benson

    * Author for correspondence

    Cambridge Breast Unit, Addenbrookes Hospital, Hills Road, & University of Cambridge, Cambridge CB2 0QQ, UK.

    &
    Ismail Jatoi

    Division of Surgical Oncology, Dale H Dorn Chair in Surgery, University of Texas Health Science Center, San Antonio, TX, USA

    Published Online:https://doi.org/10.2217/fon.12.61

    Breast cancer now represents the most common female malignancy in both the developing and developed world, and is the primary cause of death among women globally. Despite well-documented reductions in mortality from breast cancer during the past two decades, incidence rates continue to increase and do so more rapidly in countries that historically had low rates. This has emphasized the importance of survivorship issues and optimal management of disease chronicity. This article reviews current trends of incidence and mortality in both a western and global context, and considers pertinent changes in underlying etiological risk factors. The latter not only offer clues regarding changes in incidence patterns, but also provides rationale and guidance for strategies that could potentially reduce the burden of this disease. The relevance of lifestyle adjustments and screening interventions for primary and secondary prevention, respectively, are discussed with reference to different healthcare resource settings.

    Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

    References

    • Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 2008, England (Edition No. MB1 39). Office for National Statistics. National Statistics, London, UK (2010).
    • Jatoi I, Anderson WF. Breast cancer overdiagnosis with screening mammography. Arch. Int. Med.169,999–1000 (2009).
    • Waller M, Moss S, Watson J et al. The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. Cancer Epidemiol. Biomarkers Prev.16,2257–2261 (2007).
    • Roussouw JE, Anderson GL, Prentice RL et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288,321–333 (2002).
    • Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast cancer incidence in 2003 in the United States. N. Engl. J. Med.356,1670–1674 (2007).▪▪ Important although slightly controversial paper documenting the decrease in breast cancer incidence in the USA and the link with hormone replacement therapy.
    • Desantis C, Howlader N, Cronin KA et al. Breast cancer incidence rates in US women are no longer declining. Cancer Epidemiol. Biomarkers Prev.20,733–739 (2011).
    • Zahl PH, Maehlen JA. A decline in breast cancer incidence. N. Engl. J. Med.357,509–513 (2007).
    • Elfenbein GJ. A decline in breast cancer incidence. N. Engl. J. Med.357,509–513 (2007).
    • Bodmer WF. Inherited susceptibility to cancer. In: Introduction to the Cellular and Molecular Biology of Cancer (2nd Edition). Frank LM, Teich NM (Eds). Oxford University Press, NY, USA, 98–124 (1995).
    • 10  Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100,57–70 (2000).
    • 11  Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet.16(Spec No 1),R50–R59 (2007).
    • 12  Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med.353,1784–1792 (2005).
    • 13  Porter P. ‘Westernizing’ women’s risks? Breast cancer in lower income countries. N. Engl. J. Med.358,213–216 (2008).▪ Interesting and insightful article on the changing trends of breast cancer incidence and mortality in less-developed countries.
    • 14  Coleman MP, Quaresma M, Berrino F et al. Cancer survival in five continents: a worldwide population-based study. Lancet Oncol.9,730–756 (2008).
    • 15  Linos E, Spanos D, Rosner BA et al. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J. Natl Cancer Inst.100,1352–1360 (2008).
    • 16  Hery C, Ferly J, Boniol M et al. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with caucasian majority populations. Ann. Oncol.19,1009–1018 (2008).
    • 17  Autier P, Boniol M, La Vecchia C et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. Br. Med. J.341,C4480 (2010).
    • 18  Barnett GC, Shah M, Redman K et al. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J. Clin. Oncol.26,3310–3316 (2008).
    • 19  Holmberg L, Iversen OE, Rudenstam CM et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst.100,475–482 (2008).▪▪ Authoritative article on increased risk of recurrence in breast cancer related to hormone replacement therapy use.
    • 20  Danaei G, Vander Hoorn S, Lopez AD et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet366,1784–1793 (2005).
    • 21  La Vecchia C. The impact of lifestyle on breast cancer. 7th European Breast Cancer Conference. Barcelona, Spain, 24–27 March 2010.
    • 22  Bianchini F, Kaaks R, Vainio H. Overweight, obesity and cancer risk. Lancet Oncol.3,565–574 (2002).
    • 23  Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet371,569–578 (2008).
    • 24  Berclaz G, Li S, Price KN et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann. Oncol.15,875–884 (2004).
    • 25  Calle EE, Rodriguez C, Walker-Thurmand K et al. Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med.348,1625–1638 (2003).
    • 26  Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J. Clin. Oncol.29,2301–2304 (2011).▪ Provocative paper emphasizing the time-dependent effects of adjuvant therapies in hormone receptor-positive breast cancer and the rationale for extended adjuvant endocrine therapies.
    • 27  Allen NE, Beral V, Casabonne D et al. Moderate alcohol intake and cancer incidence in women. J. Natl Cancer Inst.101,296–305 (2009).
    • 28  Kwan ML, Kushi LH, Weltzien E et al. Alcohol consumption and breast cancer recurrence and survival among women with early stage breast cancer: the life after cancer epidemiology study. J. Clin. Oncol.28(29),4410–4416 (2010).▪ Seminal paper confirming the significantly elevated risk of recurrence from moderate alcohol consumption in breast cancer survivors.
    • 29  Sprague BL, Trentham-Dietz A, Newcomb PA et al. Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol. Biomarkers Prev.16(2),236–243 (2007).
    • 30  Holmes MD, Chen WY, Feskanich D et al. Physical activity and survival after breast cancer diagnosis. JAMA293(20),2479–2486 (2005).
    • 31  Hesketh T, Lu L, Xing ZW. The effect of China’s one-child family policy after 25 years. N. Engl. J. Med.353,1171–1176 (2005).
    • 32  Sankaranarayanan R, Ramadas K, Thara S et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J. Natl Cancer Inst.103(19),1476–1480 (2011).▪▪ Important paper showing the potential for clinical breast examination to reduce mortality in less-developed countries.
    • 33  Anderson BO, Shyyan R, Enui A et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Intiative 2005 guidelines. Breast J.12(Suppl. 1),S3–S15 (2006).
    • 34  Adami HO, Hansen J, Jung B, Rimsten AJ. Age at first birth, parity and risk of breast cancer in a Swedish population. Br. J. Cancer42,651–658 (1980).
    • 35  Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc. Soc. Exp. Biol. Med.216,28–43 (1997).
    • 36  Anderson WF, Matsuno RK, Sherman ME et al. Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes Control18,439–447 (2007).
    • 101  WHO. Fact sheet no. 297 (February 2011). www.who.int/mediacentre/factsheets/fs297/en/
    • 102  Cancer Stats. Breast cancer – UK incidence statistics. http://info.cancerresearchuk.org/cancerstats/▪ Authoritative source of cancer statistics and facts for UK population.